Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype

Simply Wall St.11-27

Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586210175?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-11-27 14:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586210175","market":"sg","top_or_hot":-1,"title":"Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype","media":"Simply Wall St.","content":"<div>\n<p>Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-27 14:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo","article_id":"2586210175","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586210175","pubTimestamp":1764225234,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal stromal tumors.\nSee our latest analysis for Ascentage Pharma Group International.\nFollowing the announcement of encouraging new results for olverembatinib, Ascentage Pharma Group International has continued to capture investor attention, even as its share price has pulled back 6.4% over the past...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06855":"亚盛医药-B","BK1574":"生物医药B类股"},"translate_title":"在Olverembatinib治疗罕见GIST亚型的主要数据发布后，评估亚盛医药（SEHK：6855）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal stromal tumors. See our latest analysis for Ascentage Pharma Group International. Following the announcement of encouraging new results for olverembatinib, Ascentage Pharma Group International has continued to capture investor attention, even as its share price has pulled back 6.4% over the past month. Despite short-term swings, overall momentum remains strong. This is highlighted by a 44.8% year-to-date share price return and a 49.1% total return over the past year, which suggests that long-term optimism is firmly intact and recent advances are building interest in its pipeline. If you're interested in uncovering more biotech and pharma companies making clinical breakthroughs, take a look at our curated picks using the See the full list for free.. With such strong clinical progress and robust share price gains over the past year, the big question now is whether Ascentage Pharma remains undervalued and presents a buying opportunity, or if the market has already priced in this future growth. AdvertisementMost Popular Narrative: 31.7% Undervalued The most commonly followed narrative values Ascentage Pharma Group International at a significant premium to its last close price. This highlights high expectations for future growth and major catalysts just ahead. This view does not come without bold assumptions behind the optimism, given the current fundamentals and market positioning.  Ascentage Pharma's collaboration with Takeda on Olverembatinib has the potential to expand the drug's global market reach significantly. The agreement could generate substantial milestone payments and royalties, positively impacting revenue and earnings.  Read the complete narrative. Want to know why analysts are betting on a radically higher valuation? This narrative hinges on runaway growth, big profit margin shifts, and a future profit multiple that is rare in biotech. Curious what daring financial forecasts are baked in to reach this number? Find out what really justifies the story by reading the full narrative. Result: Fair Value of $92.81 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, sustained heavy R&D spending and reliance on large one-time payments could challenge consistent profitability if revenue growth slows or if competition intensifies. Find out about the key risks to this Ascentage Pharma Group International narrative. Another View: Is the Premium Justified? Looking through the lens of traditional market ratios, Ascentage Pharma is trading at a Price-to-Book Ratio of 31.9x, which is notably higher than both the Hong Kong Biotechs industry average (4.9x) and its peers (5.8x). Such a steep premium signals the market's high expectations, but also amplifies valuation risks if growth stumbles. What happens if the optimism turns out to be overestimated? See what the numbers say about this price — find out in our valuation breakdown. SEHK:6855 PB Ratio as at Nov 2025 Build Your Own Ascentage Pharma Group International Narrative If you see things differently or want to dig into the numbers yourself, you can quickly build your own perspective and test your thesis in just a few minutes. Do it your way. A great starting point for your Ascentage Pharma Group International research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? Smart investors never limit themselves. There are exceptional opportunities beyond the headlines waiting for you. Don’t let great stocks slip through your fingers.  Tap into the future of secure finance by checking out these 81 cryptocurrency and blockchain stocks with influence in blockchain and digital payments. Unlock steady income potential by reviewing these 15 dividend stocks with yields > 3% overflowing with robust yields and reliable cash flows. Spot untapped growth stories by examining these 27 quantum computing stocks companies pioneering next-wave computing breakthroughs.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586210175","isCrawlerRequest":true}